Detalles de la búsqueda
1.
Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids.
Br J Clin Pharmacol
; 88(12): 5257-5268, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695781
2.
Risankizumab: Mechanism of action, clinical and translational science.
Clin Transl Sci
; 17(1): e13706, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38266061
3.
Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis.
Clin Pharmacol Ther
; 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38863178
4.
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
Clin Pharmacokinet
; 62(4): 623-634, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36905528
5.
Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development.
AAPS J
; 24(2): 39, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35230556
6.
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Clin Pharmacokinet
; 61(4): 577-587, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34878624
7.
A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data.
CPT Pharmacometrics Syst Pharmacol
; 10(1): 40-47, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33200566
8.
Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
Clin Transl Sci
; 14(4): 1611-1619, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963686
9.
Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women.
Clin Transl Sci
; 14(4): 1452-1463, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33650259
10.
Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
CPT Pharmacometrics Syst Pharmacol
; 9(8): 466-475, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32621325
11.
Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
CPT Pharmacometrics Syst Pharmacol
; 9(11): 639-648, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32945631
12.
Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.
Clin Pharmacol Ther
; 107(4): 994-1003, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31610021
13.
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Clin Pharmacokinet
; 59(3): 297-309, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31749075
14.
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
Clin Pharmacokinet
; 57(10): 1295-1306, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29476499
Resultados
1 -
14
de 14
1
Próxima >
>>